北京
åŒ—äº¬å•†å ±è¨Šï¼ˆè¨˜è€… 王寅浩）4月8日，云å—白藥發布公告稱，公å¸çš„全資åå…¬å¸äº‘æ ¸é†«è—¥ï¼ˆå¤©æ´¥ï¼‰æœ‰é™å…¬å¸è¿‘æ—¥ç²å¾—國家藥å“監ç£ç®¡ç†å±€æ‰¹æº–，INR102注射液的臨床試驗申請符åˆè—¥å“注冊è¦æ±‚，ç²æº–開展é‡å°å‰åˆ—腺癌的臨床試驗。該藥å“çš„å—ç†è™Ÿç‚ºCXHL2500121，通知書編號為2025LP01012，屬于化å¸è—¥å“1類，劑型為注射劑，è¦æ ¼ç‚º740MBq/mL。
特別è²æ˜Žï¼šä»¥ä¸Šå…§å®¹(å¦‚æœ‰åœ–ç‰‡æˆ–è¦–é »äº¦åŒ…æ‹¬åœ¨å…§)為自媒體平臺“網易號â€ç”¨æˆ¶ä¸Šå‚³å¹¶ç™¼å¸ƒï¼Œæœ¬å¹³è‡ºåƒ…æ供信æ¯å˜å„²æœå‹™ã€‚
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
